Spyre Therapeutics
SYRE
SYRE
85 hedge funds and large institutions have $189M invested in Spyre Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
0.07% less ownership
Funds ownership: 3.31% → 3.24% (-0.07%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
41% less capital invested
Capital invested by funds: $322M → $189M (-$133M)
Holders
85
Holding in Top 10
2
Calls
$263K
Puts
$248K
Top Buyers
| 1 | +$6.16M | |
| 2 | +$4.01M | |
| 3 | +$1.96M | |
| 4 |
D.E. Shaw & Co
New York
|
+$946K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$832K |
Top Sellers
| 1 | -$11.9M | |
| 2 | -$5.03M | |
| 3 | -$1.64M | |
| 4 |
ACM
Altium Capital Management
New York
|
-$1.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.3M |